TrialNature communications2024

Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial.

Hongli Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.